LACTOLOGY FOUNDATION

A04AD12 comprises neurokinin‑1 (NK1) receptor antagonists used as antiemetics, with aprepitant as the reference substance; available data suggest low expected exposure in breastfed infants but evidence is limited, so use in lactation must be individualized and cautious.medpedia.framar+4

Pharmacological class and agents (A04AD12)

A04AD12 belongs to the ATC group “Other antiemetics,” specifically NK1 receptor antagonists that block substance P at NK1 receptors in the central nervous system.drugbank+2
Aprepitant is the prototypical agent in this class and is used to prevent nausea and vomiting associated with highly and moderately emetogenic chemotherapy and postoperative nausea and vomiting, usually in combination with a 5‑HT3 antagonist and a corticosteroid.mayoclinic+4

Mechanism of action and pharmacodynamics

Aprepitant is a selective, high‑affinity NK1 receptor antagonist that inhibits the action of substance P in the vomiting centre and related pathways, reducing both acute and delayed phases of chemotherapy‑induced emesis.drugbank+2
It is used as part of combination regimens, enhancing control of nausea and vomiting when added to serotonin 5‑HT3 antagonists and corticosteroids, but continuous chronic administration is not recommended.accessdata.fda+3

Clinical use, dosing and general safety

Aprepitant is indicated for prevention of chemotherapy‑induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV), not for treatment of established vomiting.medpedia.framar+2
Typical adult oral CINV regimens use 125 mg one hour before chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3; 40 mg orally within three hours before anaesthesia is recommended for PONV prophylaxis.medsafe+3

Adverse effects include hypersensitivity reactions, hiccups, fatigue, headache, constipation and decreased appetite, mostly mild to moderate in intensity.mims+2
Aprepitant is contraindicated in patients with hypersensitivity to the active substance or excipients, and caution is advised in hepatic impairment.mims+2

Drug interactions and reproductive safety (non‑lactation)

Aprepitant is a moderate inhibitor and inducer of CYP3A4 and can significantly increase exposure to co‑administered corticosteroids, so their doses are usually reduced when given in combination.accessdata.fda+2
It may decrease the efficacy of hormonal contraceptives during therapy and for up to 28 days after the last dose, necessitating additional non‑hormonal contraceptive measures.medsafe+2

In pregnancy, human safety data remain limited; aprepitant is used only when the potential benefit to the mother outweighs possible fetal risks, typically within oncology or peri‑operative settings.ncbi.nlm.nih+1
Preclinical data show excretion into the milk of lactating rats, signalling potential exposure for offspring but not defining human risk.europa+1

Toxicological‑lactological profile

Transfer into breast milk and infant exposure

No quantitative human data are available on aprepitant concentrations in breast milk, and no published clinical series describe breastfed infants exposed to this drug.ncbi.nlm.nih+2
Because aprepitant is more than 95% bound to plasma proteins and has high molecular weight, passive transfer into human milk is expected to be low, limiting the theoretical infant dose.drugbank+1

Animal studies have demonstrated excretion of aprepitant into rat milk, but extrapolation to humans is uncertain due to interspecies differences in lactation physiology.europa+1
Regulatory product information from several authorities states that it is not known whether aprepitant is excreted in human milk and often formally advises against breastfeeding during treatment, mainly out of precaution.e-lactancia+3

Lactation risk assessment and recommendations

LactMed concludes that, despite the lack of human data, the pharmacokinetic profile suggests low milk levels and that the need for aprepitant is not, by itself, a reason to discontinue breastfeeding.ncbi.nlm.nih
However, lactation risk assessment must also consider the underlying indication, particularly concomitant chemotherapy, where the overall treatment regimen may render breastfeeding inappropriate or unsafe.ncbi.nlm.nih+1

StatPearls and regulatory sources highlight that there are no adequate human studies evaluating infant harm or longer‑term developmental effects after exposure to NK1 antagonists through breast milk.accessdata.fda+2
Given this uncertainty, use during breastfeeding should be short‑term, at the lowest effective dose, with careful monitoring of the infant for sedation, feeding difficulties, gastrointestinal disturbances or unusual behaviour.ncbi.nlm.nih+1

In practice, single‑course peri‑operative or chemotherapy‑associated aprepitant in a full‑term healthy infant context may be considered compatible with breastfeeding if the maternal clinical benefit is substantial and alternative antiemetics are unsuitable.ncbi.nlm.nih+1
In contrast, continuous or repeated long‑term use is discouraged during lactation, and many official product labels recommend avoiding breastfeeding during treatment and for a short period afterwards.e-lactancia+2

Practical toxicological‑lactological guidance for A04AD12 drugs

For A04AD12 NK1 antagonists, clinicians should first evaluate whether the antiemetic benefit is critical, especially in highly emetogenic chemotherapy where uncontrolled vomiting would jeopardize treatment and maternal health.drugbank+2
When aprepitant is selected, they should review concomitant medications (corticosteroids, hormonal contraceptives and other CYP3A4 substrates) to anticipate interactions that may influence both maternal and infant risk.medpedia.framar+2

In breastfeeding women receiving sporadic peri‑operative aprepitant without cytotoxic chemotherapy, continuation of breastfeeding may be reasonable, particularly for term, healthy infants, provided individual risk–benefit analysis and parental counselling are documented.ncbi.nlm.nih+1
In oncology settings, the overall chemotherapy regimen, not aprepitant alone, usually dictates whether breastfeeding must be interrupted, often resulting in a temporary or permanent cessation independent of the NK1 antagonist.ncbi.nlm.nih+1

Healthcare professionals should clearly communicate that evidence gaps persist, explain the theoretical basis for low milk transfer, and involve the mother in shared decision‑making that respects her preferences and the infant’s safety.e-lactancia+2
Monitoring plans should include observation of the infant’s feeding pattern, weight gain, gastrointestinal symptoms and alertness for several days after maternal dosing, especially with multi‑day regimens.ncbi.nlm.nih+1